About: Nonsense-Mediated mRNA Decay: Pathologies and the Potential for Novel Therapeutics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nonsense-Mediated mRNA Decay: Pathologies and the Potential for Novel Therapeutics Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Nonsense-Mediated mRNA Decay: Pathologies and the Potential for Novel Therapeutics
Creator	Alfaro, Javier Kalathiya, Umesh Pawlicka, Kamila
source	Medline; PMC
abstract	Nonsense-mediated messenger RNA (mRNA) decay (NMD) is a surveillance pathway used by cells to control the quality mRNAs and to fine-tune transcript abundance. NMD plays an important role in cell cycle regulation, cell viability, DNA damage response, while also serving as a barrier to virus infection. Disturbance of this control mechanism caused by genetic mutations or dys-regulation of the NMD pathway can lead to pathologies, including neurological disorders, immune diseases and cancers. The role of NMD in cancer development is complex, acting as both a promoter and a barrier to tumour progression. Cancer cells can exploit NMD for the downregulation of key tumour suppressor genes, or tumours adjust NMD activity to adapt to an aggressive immune microenvironment. The latter case might provide an avenue for therapeutic intervention as NMD inhibition has been shown to lead to the production of neoantigens that stimulate an immune system attack on tumours. For this reason, understanding the biology and co-option pathways of NMD is important for the development of novel therapeutic agents. Inhibitors, whose design can make use of the many structures available for NMD study, will play a crucial role in characterizing and providing diverse therapeutic options for this pathway in cancer and other diseases.
has issue date	2020-03-24(xsd:dateTime)
bibo:doi	10.3390/cancers12030765
bibo:pmid	32213869
has license	cc-by
sha1sum (hex)	5817479c9aa2b32021af3d294075e71f2fc9b873
schema:url	https://doi.org/10.3390/cancers12030765
resource representing a document's title	Nonsense-Mediated mRNA Decay: Pathologies and the Potential for Novel Therapeutics
has PubMed Central identifier	PMC7140085
has PubMed identifier	32213869
schema:publication	Cancers (Basel)
resource representing a document's body	covid:5817479c9aa2b32021af3d294075e71f2fc9b873#body_text
is schema:about of	named entity 'cell cycle regulation' named entity 'mRNA' named entity 'downregulation' named entity 'NMD' named entity 'messenger RNA' named entity 'Cancer cells' named entity 'dys' named entity 'virus infection' named entity 'NMD' named entity 'NMD' named entity 'tumour suppressor genes' named entity 'Nonsense-Mediated' named entity 'homeobox' named entity 'EJC' named entity 'red blood cells' named entity 'evolution' named entity 'alternatively spliced' named entity 'asymptomatic' named entity 'three-dimensional spheres' named entity 'NMD' named entity 'chronic inflammation' named entity 'NMD pathway' named entity 'homeostasis' named entity 'ribonucleoprotein' named entity 'cancer development' named entity 'tumour microenvironment' named entity 'RNAi' named entity 'epithelial-to-mesenchymal transition' named entity 'mRNAs' named entity 'NMD' named entity 'alternative splicing' named entity 'NMD pathway' named entity 'mRNAs' named entity 'UPF3b' named entity 'snoRNA' named entity 'NMD' named entity 'unfolded protein response' named entity 'Three-dimensional protein structures' named entity 'RRM' named entity 'NMD' named entity 'ribosome' named entity 'UPF3a' named entity 'SMG5' named entity 'mammalian cells' named entity 'embryonic development' named entity 'NMD' named entity 'malignancy' named entity 'UPF1' named entity 'mRNAs' named entity 'immune response' named entity 'gene' named entity 'SMG1' named entity 'lymphocytes' named entity 'Nonsense-mediated mRNA decay' named entity 'schizophrenia' named entity 'human T-cell lymphotropic virus' named entity 'mRNA transcription' named entity 'protein-protein' named entity 'drug discovery' named entity 'neurological' named entity 'NMD' named entity 'cystic fibrosis' named entity 'interacting proteins' named entity 'NMD' named entity 'hereditary diffuse gastric cancer' named entity 'UPF1' named entity 'small molecule' named entity 'NMD' named entity 'RNA' named entity 'NMD' named entity 'NMD' named entity 'antitumour' named entity 'UPF1' named entity 'nude mice' named entity 'exon' named entity 'protein' named entity 'UPF3b' named entity 'dominant negative mutation' named entity 'tumourigenesis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software